Pneumovax® 23

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC, Canadian Immunization Research Network

Conditions

Acute Lymphoblastic LeukemiaPneumococcal Infections

Phase 2

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

CompletedNCT01513551

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2012-03-13End: 2013-02-15Updated: 2018-12-13

Phase 4

Vaccinating Children After Chemotherapy

CompletedNCT02447718

Canadian Immunization Research NetworkAcute Lymphoblastic Leukemia

Start: 2015-11-16End: 2018-03-05Updated: 2022-06-24

Related Papers

Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study

Clinical Infectious Diseases2020-02-1322 citations

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.

2018-03-1732 citations